Abstract
Abstract: GCI-132-N is a non-invasive, wearable ultrasound platform designed for superior ocular neuroprotection and disease monitoring, primarily targeting glaucoma but with applicability to early Parkinson's and Alzheimer's biomarker tracking. This GEN-1.2 dossier presents an industrial blueprint leveraging sonoporation physics, commercial-off-the-shelf (COTS) hardware, and a proprietary Caldwell-Carrier Neuro-Gel with microbubbles. Key features include a 64-element CMUT array for dual-frequency vortex sonoporation, a graphene thermal spreader, PDMS microfluidics for gel refresh, and a self-powered hybrid energy system. A "Caldwell Resonance Signature" customizes ultrasound delivery to individual ocular impedance profiles, enhancing efficiency by 30%. Real-time safety is ensured via triple-redundant interlocks, including pressure, temperature, and corneal impedance monitoring. Glaucoma neuroprotection is achieved through 10-20x enhanced delivery of Citicoline and Brimonidine to retinal ganglion cells. Disease progression is quantitatively tracked via a smartphone-integrated lateral flow assay for Neurofilament Light (NFL) concentration in tears. The system is designed for a 15-minute daily session and targets FDA 510(k) clearance by Q4 2026, with first human trials in Q2 2027. This document details the complete Bill of Materials, hardware and software architectures, clinical protocols, patient instructions, safety measures, and a 12-month execution timeline, positioning GCI-132-N as an industrial-ready product for the eradication of blindness through open-source mechanical restoration.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
Recommended Citation
Caldwell, Michael Victor Mr., "GCI-132-N GEN-1.2: Omni-Restoration Platform for Non-Invasive Ocular Neuroprotection and Disease Monitoring", Technical Disclosure Commons, ()
https://www.tdcommons.org/dpubs_series/9518